These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 22846396

  • 21. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 22. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial.
    Uno S, Kimachi K, Kei J, Miyazaki K, Oohama A, Nishimura T, Ibaragi K, Odoh K, Kudo Y, Kino Y.
    Microbiol Immunol; 2011 Nov 17; 55(11):783-9. PubMed ID: 21895745
    [Abstract] [Full Text] [Related]

  • 23. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, Lin TY, Huang LM.
    Vaccine; 2010 Aug 16; 28(36):5864-70. PubMed ID: 20600484
    [Abstract] [Full Text] [Related]

  • 24. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV, Pariani E, Scaramuzza A, Santoro L, Giani E, Macedoni M, Gazzarri A, Anselmi G, Amendola A, Zanetti A.
    Diabet Med; 2011 Dec 16; 28(12):1530-6. PubMed ID: 21916971
    [Abstract] [Full Text] [Related]

  • 25. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
    Kung HC, Huang KC, Kao TM, Lee YC, Chang FY, Wang NC, Liu YC, Lee WS, Liu HJ, Chen CI, Chen CH, Huang LM, Hsieh SM.
    Vaccine; 2010 Oct 21; 28(45):7337-43. PubMed ID: 20817013
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn PM, McCullers JA.
    Vaccine; 2012 Jan 20; 30(5):879-85. PubMed ID: 22155630
    [Abstract] [Full Text] [Related]

  • 27. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 20; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 28. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
    Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, Ahn YJ, Kim SH, Lee HJ.
    Vaccine; 2010 Aug 16; 28(36):5857-63. PubMed ID: 20600483
    [Abstract] [Full Text] [Related]

  • 29. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.
    Vaccine; 2009 Oct 23; 27(45):6291-5. PubMed ID: 19840662
    [Abstract] [Full Text] [Related]

  • 30. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.
    Vaccine; 2012 Jul 13; 30(33):5009-18. PubMed ID: 22658967
    [Abstract] [Full Text] [Related]

  • 31. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M, Leroux-Roels G, Rümke H, Rivera L, Pedotti P, Arora AK, Lattanzi M, Kieninger D, Cioppa GD.
    Hum Vaccin Immunother; 2015 Jul 13; 11(2):358-76. PubMed ID: 25621884
    [Abstract] [Full Text] [Related]

  • 32. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.
    Vaccine; 2011 Nov 15; 29(49):9209-13. PubMed ID: 21974995
    [Abstract] [Full Text] [Related]

  • 33. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I.
    Vaccine; 2010 Apr 19; 28(18):3076-9. PubMed ID: 20193791
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Clinical development of a Vero cell culture-derived seasonal influenza vaccine.
    Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.
    Vaccine; 2012 Jun 19; 30(29):4377-86. PubMed ID: 22172502
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of intradermal influenza vaccine in children.
    Esposito S, Daleno C, Picciolli I, Tagliaferri L, Scala A, Prunotto G, Montinaro V, Galeone C, Principi N.
    Vaccine; 2011 Oct 13; 29(44):7606-10. PubMed ID: 21855592
    [Abstract] [Full Text] [Related]

  • 38. Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
    Duval X, Caplanusi A, Laurichesse H, Deplanque D, Loulergue P, Vaman T, Launay O, Gillard P.
    BMC Infect Dis; 2012 Jul 23; 12():162. PubMed ID: 22824474
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
    Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R.
    Hum Vaccin Immunother; 2012 Jul 23; 8(7):921-8. PubMed ID: 22777094
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.